First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA)

First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA) DREAM is a pivotal, Investigational Device Exemption (IDE) study, designed to support marketing authorization in the United States Mont-Saint-Guibert, Belgium – 5th January 2021 – Nyxoah S.A. (EBR: NYXH) (“Nyxoah” or the “Company”), […]